Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating Expenses:        
Research and development $ 972,113 $ 583,177 $ 2,339,863 $ 1,688,474
Research and development - related parties 132,881 53,347 481,027 158,401
General and administrative 2,433,193 3,418,628 9,204,122 10,405,933
General and administrative - related parties 5,261
Total Operating Expenses 3,538,187 4,055,152 12,025,012 12,258,069
Loss From Operations (3,538,187) (4,055,152) (12,025,012) (12,258,069)
Other Income (Expense):        
Interest expense (11,634) (7,348) (34,796) (22,117)
Interest (expense) income – related parties (1,536) 1,495
Loss on goodwill impairment (18,872,850) (18,872,850)
Loss on IP R&D asset impairment (9,063,000) (9,063,000)
Change in fair value of derivative liabilities 2,036 1,449,908 69,776 14,167,560
Total Other Expense, Net (9,072,598) (17,431,826) (9,028,020) (4,725,912)
Net Loss Before Income Taxes (12,610,785) (21,486,978) (21,053,032) (16,983,981)
Income tax benefit 2,345,025 2,345,025
Net Loss (10,265,760) (21,486,978) (18,708,007) (16,983,981)
Other Comprehensive (Loss) Income:        
Foreign currency translation adjustments 51,316 (1,871,072) 36,712 (4,507,204)
Total Comprehensive Loss $ (10,214,444) $ (23,358,050) $ (18,671,295) $ (21,491,185)
Basic and Diluted Net Loss per Common Share        
Basic (in Dollars per share) $ (1.29) $ (10.97) $ (3.31) $ (9.49)
Diluted (in Dollars per share) $ (1.29) $ (10.97) $ (3.31) $ (9.49)
Weighted Average Number of Common Shares Outstanding:        
Basic (in Shares) 7,951,954 1,959,087 5,658,831 1,790,176
Diluted (in Shares) 7,951,954 1,959,087 5,658,831 1,790,176